Immunocore (NASDAQ:IMCR) Stock Price Up 5% - Still a Buy?

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) was up 5% on Monday . The company traded as high as $29.92 and last traded at $29.82. Approximately 215,824 shares were traded during trading, a decline of 29% from the average daily volume of 305,470 shares. The stock had previously closed at $28.41.

Analyst Upgrades and Downgrades

IMCR has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research note on Monday, April 14th. Mizuho cut their target price on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. Morgan Stanley reiterated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Immunocore in a report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, Immunocore presently has an average rating of "Moderate Buy" and a consensus target price of $60.90.

Immunocore Stock Up 1.8 %

The business's 50 day simple moving average is $28.75 and its 200 day simple moving average is $30.35. The company has a market capitalization of $1.55 billion, a PE ratio of -32.39 and a beta of 0.75. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Insider Buying and Selling

In other Immunocore news, Director Bros. Advisors Lp Baker acquired 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the purchase, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On Immunocore

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in Immunocore by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock valued at $1,047,000 after buying an additional 420 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Immunocore in the fourth quarter worth $25,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after acquiring an additional 960 shares during the last quarter. NEOS Investment Management LLC raised its holdings in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares in the last quarter. Finally, Assetmark Inc. boosted its position in Immunocore by 5.3% during the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company's stock valued at $949,000 after purchasing an additional 1,616 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.